Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free, as long as they provide 'training data' to refine them. The new launch – ...
FUJISAWA, Japan, June 18, 2026--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) is pleased to announce that it has entered a collaboration with Lilly TuneLab, a collaborative AI ...
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) is pleased to announce that it has entered a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Aribio said on the 7th that it will join Eli Lilly and Company's artificial intelligence (AI)-based drug discovery platform Lilly TuneLab™. Accordingly, the company plans to combine more than 10 years ...
BURLINGAME, Calif., May 20, 2026 /PRNewswire/ -- Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today ...
Lilly created Lilly TuneLab to accelerate biotech innovation by enabling participating companies to access models trained on Lilly’s proprietary research data. Through this agreement, biotech ...
Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The ...
The MarketWatch News Department was not involved in the creation of this content. -- Vasa's CAMKII delta inhibitor, a leading discovery and development platform built on extensive crystallography data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results